Pfizer Targets PF-08634404 Trials and MET-097i Phase 3 While Forecasting Flat 2026 Revenue
Pfizer’s 2026 revenue guidance of $59.5–$62.5 billion implies flat to slightly lower sales versus projected $62 billion in 2025, pressured by a weak COVID-19 vaccine franchise. Next year could see oncology advances from PF-08634404 late-stage trials and MET-097i’s phase 3 weight-loss and diabetes studies after successful phase 2 data.
1. Progress in Oncology
Pfizer’s oncology franchise is positioned for a breakthrough in 2026 following its $43 billion acquisition of Seagen and the in-licensing of PF-08634404 from 3SBio. The company has accelerated PF-08634404 into multiple late-stage trials and plans interim analyses from phase 3 studies as well as readouts from phase 2 programs. With over 60 oncology candidates in its pipeline, positive data on PF-08634404 could position Pfizer to challenge market leaders such as Keytruda in key indications, potentially adding billions in annual sales by the end of the decade and reinvigorating investor confidence in its long-term growth trajectory.
2. Advances in Weight-Management Drugs
Pfizer is targeting the rapidly expanding obesity market with a diversified portfolio of GLP-1 therapies. Oral candidate PF-07976016 is in phase 2 studies, while MET-097i—acquired through a strategic deal—delivered strong phase 2 efficacy and tolerability, and is slated to enter phase 3 trials for both weight loss and type 2 diabetes in 2026. The once-monthly dosing profile of MET-097i, if confirmed, would distinguish it from weekly injectables and could capture a significant share of a market projected to exceed $100 billion by 2030. Additionally, the recently licensed YP05002 is advancing through phase 1, further hedging Pfizer’s exposure across multiple modalities and clinical stages.
3. Financial Outlook and Strategic Guidance
For full-year 2026, Pfizer has guided to revenue of $59.5 billion–$62.5 billion versus its prior $62 billion projection, reflecting a continued downturn in its COVID-19 vaccine franchise as public health policies evolve. Gross margins are expected to stabilize near current levels, supported by cost-savings initiatives targeting $4 billion over two years. R&D investment will remain elevated—forecast at $10.5 billion–$11.5 billion—to fund the accelerated development of oncology and obesity assets. While near-term top-line growth is projected to be flat, the company underscores a five-year investment horizon, betting that late-stage progress in PF-08634404 and MET-097i will drive meaningful revenue upside and restore earnings momentum.